gemcitabine-polyacetal conjugate

Gemcitabine-polyacetal conjugate is an experimental polymer-drug conjugate designed for the targeted treatment of pancreatic cancer. Developed by researchers at Columbia University, the therapy consists of the cytotoxic nucleoside analog gemcitabine covalently linked to a temperature-responsive polyacetal polymer. This delivery system is engineered to remain inert at physiological pH but undergoes selective degradation and drug release in the acidic microenvironment characteristic of solid tumors (e.g., pH 6.8). By sequestering gemcitabine in an inactive form until it reaches the tumor site, the conjugate aims to improve drug penetration into stroma-rich hypovascular tumors while minimizing systemic toxicity and off-target effects.

Other names

gemcitabine-polyacetal drug conjugatepolyacetal-gemcitabine conjugate